title: Plasmatic haemostasis in gonadotrophin-releasing hormone analogue therapy: effects of leuprorelin acetate depot on coagulatory and fibrinolytic activities.
abstract: The plasmatic parameters of coagulatory and fibrinolytic activity were studied in 15 patients with biopsy-proven endometriosis treated with leuprorelin acetate for 6 months. Bleeding time remained constant, indicating the absence of increased bleeding tendencies. The activity of the main inhibitor of the fibrinolytic response, plasminogen activator inhibitor, was reduced by 25%, suggesting an improvement in fibrinolytic reactivity. Plasma levels of fibrin degradation fragments were reduced by 35%, suggesting a marked reduction in the rate of fibrin generation and degradation. A simultaneous reduction in thrombin-antithrombin III complexes and prothrombin fragment 1 + 2 (-10%) indicated that this effect was induced by reduced procoagulant activity, ie, thrombin generation. These data indicate that in gonadotrophin-releasing hormone (Gn-RH) analogue therapy the basal rate of coagulatory processes is reduced. The frequency and extent of fibrin-generating and degrading processes are reduced, suggesting a beneficial effect of Gn-RH analogues on the risk of thromboembolic disease.
authors.affiliation: Abteilung für Gynäkologie, Universitätsklinikum Essen, Germany.
authors.forename: U
authors.initials: U
authors.lastname: Winkler
authors.forename: K
authors.initials: K
authors.lastname: Bühler
authors.forename: S
authors.initials: S
authors.lastname: Koslowski
authors.forename: C
authors.initials: C
authors.lastname: Oberhoff
authors.forename: A E
authors.initials: AE
authors.lastname: Schindler
mesh_terms: D000990:Antithrombin III / Q000378:metabolism; D001777:Blood Coagulation / Q000187:drug effects*; D003692:Delayed-Action Preparations; D004715:Endometriosis / Q000097:blood / Q000188:drug therapy*; D005260:Female; D005340:Fibrinogen / Q000378:metabolism; D005342:Fibrinolysis / Q000187:drug effects*; D006487:Hemostasis / Q000187:drug effects*; D006801:Humans; D016729:Leuprolide / Q000627:therapeutic use*; D015849:Plasminogen Inactivators / Q000032:analysis; D013917:Thrombin / Q000378:metabolism; D014841:von Willebrand Factor / Q000378:metabolism
chemical_list: D003692:Delayed-Action Preparations; D015849:Plasminogen Inactivators; D014841:von Willebrand Factor; D000990:Antithrombin III; D005340:Fibrinogen; D013917:Thrombin; D016729:Leuprolide